Y-mAbs Therapeutics terminated its Phase 1 radioimmunotherapy trial for non-Hodgkin lymphoma patients, citing recruitment difficulties as the primary reason. The company made the decision to discontinue the study after struggling to enroll sufficient participants for the clinical investigation.
Recruitment challenges have become increasingly common in oncology trials, particularly for rare cancer indications and novel treatment modalities like radiopharmaceuticals. The competitive clinical trial landscape and stringent eligibility criteria often compound these enrollment difficulties for smaller biotech companies.